161 related articles for article (PubMed ID: 16050796)
1. TLK-286: a novel glutathione S-transferase-activated prodrug.
Tew KD
Expert Opin Investig Drugs; 2005 Aug; 14(8):1047-54. PubMed ID: 16050796
[TBL] [Abstract][Full Text] [Related]
2. TLK 286.
Drugs R D; 2004; 5(2):116-8. PubMed ID: 15293875
[TBL] [Abstract][Full Text] [Related]
3. TLK-286.
Verschraegen CF; Smith HO; Lee FC; Cathcart C; Norenberg JP
IDrugs; 2004 Aug; 7(8):771-81. PubMed ID: 15334311
[TBL] [Abstract][Full Text] [Related]
4. TLK-199 (Telik).
Hamilton D; Batist G
IDrugs; 2005 Aug; 8(8):662-9. PubMed ID: 16044376
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA).
Dourado DF; Fernandes PA; Ramos MJ; Mannervik B
Biochemistry; 2013 Nov; 52(45):8069-78. PubMed ID: 24066958
[TBL] [Abstract][Full Text] [Related]
6. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
Johansson K; Ito M; Schophuizen CM; Mathew Thengumtharayil S; Heuser VD; Zhang J; Shimoji M; Vahter M; Ang WH; Dyson PJ; Shibata A; Shuto S; Ito Y; Abe H; Morgenstern R
Mol Pharm; 2011 Oct; 8(5):1698-708. PubMed ID: 21851097
[TBL] [Abstract][Full Text] [Related]
7. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
8. Cellular response to a glutathione S-transferase P1-1 activated prodrug.
Rosario LA; O'Brien ML; Henderson CJ; Wolf CR; Tew KD
Mol Pharmacol; 2000 Jul; 58(1):167-74. PubMed ID: 10860939
[TBL] [Abstract][Full Text] [Related]
9. Epothilone D (Kosan/Roche).
Kolman A
Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
11. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
Morgan AS; Sanderson PE; Borch RF; Tew KD; Niitsu Y; Takayama T; Von Hoff DD; Izbicka E; Mangold G; Paul C; Broberg U; Mannervik B; Henner WD; Kauvar LM
Cancer Res; 1998 Jun; 58(12):2568-75. PubMed ID: 9635580
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertase inhibition: Paralyzing the cell's master switches.
Klein-Szanto AJ; Bassi DE
Biochem Pharmacol; 2017 Sep; 140():8-15. PubMed ID: 28456517
[TBL] [Abstract][Full Text] [Related]
13. Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells.
van Gisbergen MW; Cebula M; Zhang J; Ottosson-Wadlund A; Dubois L; Lambin P; Tew KD; Townsend DM; Haenen GR; Drittij-Reijnders MJ; Saneyoshi H; Araki M; Shishido Y; Ito Y; Arnér ES; Abe H; Morgenstern R; Johansson K
Mol Pharm; 2016 Jun; 13(6):2010-25. PubMed ID: 27093577
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for ovarian cancer.
Kelland LR
Expert Opin Emerg Drugs; 2005 May; 10(2):413-24. PubMed ID: 15934876
[TBL] [Abstract][Full Text] [Related]
15. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
Lee KGZ; Babak MV; Weiss A; Dyson PJ; Nowak-Sliwinska P; Montagner D; Ang WH
ChemMedChem; 2018 Jun; 13(12):1210-1217. PubMed ID: 29637702
[TBL] [Abstract][Full Text] [Related]
16. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
17. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets.
Townsend DM; Findlay VL; Tew KD
Methods Enzymol; 2005; 401():287-307. PubMed ID: 16399394
[TBL] [Abstract][Full Text] [Related]
18. Novel cytotoxic agents for non-small cell lung cancer.
Edelman MJ
J Thorac Oncol; 2006 Sep; 1(7):752-5. PubMed ID: 17409954
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: cantuzumab mertansine, ImmunoGen.
Smith SV
Curr Opin Mol Ther; 2004 Dec; 6(6):666-74. PubMed ID: 15663331
[TBL] [Abstract][Full Text] [Related]
20. CYC-202 Cyclacel.
Guzi T
Curr Opin Investig Drugs; 2004 Dec; 5(12):1311-8. PubMed ID: 15648953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
